# Vascular Surgery Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ella Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML029-SYN
- Date: 2026-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odessa Whitlow, MD
- Calendar frame: modern shifted

- To: Marcus Okafor-Lane, MD, Vascular Surgery
- Urgency: Within two to three weeks, on the same day as her two-week primary care visit

## Referral question

Claudication of both calves, worse on the right, in a 70-year-old touring singer with type 2 diabetes, coronary bypass surgery last year, and an ankle-brachial index of 0.62 right and 0.74 left. Please define the arterial disease, advise on exercise and antithrombotic therapy, and tell us whether and when revascularization should be considered, so that her limbs are protected before any tissue is lost. **S**

## Questions for the consultant

1. Where is the arterial disease, and how severe is it?
2. Is supervised exercise therapy appropriate, and how should it fit around her touring?
3. Should antithrombotic therapy change, for example low-dose rivaroxaban with aspirin?
4. Is revascularization indicated now, and what would make it indicated later?
5. How often should her arteries and feet be reviewed, and what findings need urgent vascular review?

## Pertinent history

Calf cramping after about one and a half blocks for about a year, now limiting her walks through airports and to the stage; no rest pain, wounds, or color change. Diabetes for many years with retinopathy; A1c 8.6% with low glucose readings after late shows, so glipizide was stopped today, glargine reduced to 24 units and moved to the morning, and empagliflozin started. Five-vessel coronary bypass surgery last year; no angina; on aspirin 81 mg, metoprolol succinate 25 mg, and atorvastatin, raised today from 40 to 80 mg for an LDL of 92 mg/dL. Never smoked. Examination: femoral pulses present; popliteal and foot pulses absent on the right and foot pulses faint on the left; calluses under the second metatarsal heads and hammer toes; protective sensation intact; no ulcer (IWGDF risk category 2). Ankle-brachial index 0.62 right and 0.74 left; toe-brachial index 0.46 and 0.55. Creatinine 0.92 mg/dL, eGFR 67, potassium 4.4 mmol/L; urine albumin-creatinine ratio 18 mg/g; hemoglobin 12.4 g/dL. Right macular edema; retina clinic appointment pending. She tours in the United States and overseas and wants to keep performing; she decides who is told about her health. **S**

- Ella Jane Fitzgerald was born on April 25, 1917, in Newport News, Virginia, to Temperance and William Fitzgerald. Most biographies gave 1918, but her birth certificate and school records show 1917. **D**
- In 1932 her mother died suddenly of a heart attack; orphaned at 15, she was placed in the Colored Orphan Asylum in Riverdale, New York. **D**
- In 1934 she won an amateur contest at the Apollo Theater in Harlem, which brought her to the attention of the drummer and bandleader Chick Webb; she made her first recording with his band in 1935, and her 1938 swing version of the nursery rhyme "A-Tisket, A-Tasket" became her first hit. **D**
- She won the Grammy Award for Best Jazz Individual Performance in 1958 for Ella Fitzgerald Sings the Duke Ellington Song Book, and received the Kennedy Center award for lifetime achievement in 1979. She was known as America's first lady of song. **D**
- She began to have health problems during the 1970s; she had diabetes, which caused problems with her eyes. **D**
- In the 1970s, after cataract surgery, she returned to touring more than 40 weeks a year. **D**
- In 1986 she was admitted to intensive care for heart trouble and underwent quintuple-bypass heart surgery; the following year she was back onstage. **D**

6 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Hemoglobin A1c: 8.6% (high); Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Creatinine: 0.92 mg/dL; eGFR: 67 mL/min/1.73 m²; Glucose: 168 mg/dL (high); Urine albumin-creatinine ratio: 18 mg/g; Total cholesterol: 164 mg/dL; LDL cholesterol: 92 mg/dL; HDL cholesterol: 44 mg/dL (low); Triglycerides: 140 mg/dL; ALT: 22 U/L; AST: 24 U/L; Hemoglobin: 12.4 g/dL; Vitamin B12: 386 pg/mL; Ankle-brachial index, right: 0.62 (low); Ankle-brachial index, left: 0.74 (low); Toe-brachial index, right: 0.46 (low); Toe-brachial index, left: 0.55 (low); Best-corrected visual acuity, right eye (ETDRS letters): 64 (low); Best-corrected visual acuity, left eye (ETDRS letters): 81. All results are synthetic.

BP 126/70 mmHg; pulse 62 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 84 kg; BMI 30.9 kg/m². All vital signs are synthetic.

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Insulin glargine 100 units/mL pen, 24 units under the skin each morning **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth each morning **S**
- Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose **S**

## Plan so far

- Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color change. Guideline: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explained. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%). Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHg. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materials. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformin. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touring. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
